Advances in the management of head and neck cancers – the new era of immunotherapies - Certificate of Completion

Duration

1.5 hrs

Profession

Specialist

# of Credits

1.5

Accreditation

Certificate of Completion

Expiry Date

2020-08-15

According to Cancer Australia, there were almost 5000 new cases of head and neck cancer diagnosed in Australia in 2017 making it the seventh most commonly diagnosed cancer in the country. More than 1000 Australians died from head and neck cancers during 2017, with a 5-year relative survival rate of 69% from 2009–2013. This has improved only marginally from 61% in 1984–1988. SCCHN comprises a heterogeneous group of tumours that arise from the squamous epithelium of the oral cavity, oropharynx, larynx and hypopharynx. While many SCCHNs are related to behavioural risk factors such as smoking and alcohol use, infection with HPV (predominantly HPV-16 subtype) is associated with a clinically, genomically and immunologically distinct subgroup of tumours arising from the epithelium of the tonsil and base of the tongue. HPV-positive SCCHN is becoming increasingly common in many Western countries and is associated with improved prognosis compared with HPV-negative SCCHN.

This interactive online learning activity is valued at 1.5 Hour(s) of continuing education.

Associate Professor Alex Guminski
MBBS FRACP PhD
Medical Oncologist, Melanoma Institute Australia, Sydney
North Shore Private Hospital,
Royal North Shore Hospital, Sydney, NSW

Associate Professor Brett Hughes
BSc(Med) MBBS(Hons) FRACP
Senior Staff Specialist Medical Oncologist
Royal Brisbane and Women’s Hospital and
The Prince Charles Hospital Brisbane, QLD

Après avoir complété ce programme de formation continue, le clinicien sera mieux en mesure de :

  • Cerner l’importance d’une approche multifactorielle à la pharmacothérapie pour la prise en charge du diabète de type 2, incluant la maîtrise glycémique, la réduction du poids corporel, l’accroissement de l’activité physique, l’amélioration de la dyslipidémie et la réduction du risque CV;
  • Comprendre l’importance du poids corporel dans la prise en charge du diabète de type 2 et son incidence sur le choix d’un agent antihyperglycémiant;
  • Faciliter la prise de décision clinique lorsqu’il vient temps de sélectionner la classe de médicament appropriée pour un patient particulier;
  • Distinguer les agonistes des récepteurs du GLP-1 des inhibiteurs du SGLT2 en ce qui concerne leurs effets sur la réduction du risque vasculaire;
  • Connaître l’icidence que peuvent avoir la fragilité et les degrés de fonction rénale sur la prise en charge du diabète de type 2.


Related Courses